At Data Layer Solutions, we specialise in Biostatistics and pharmaceutical data analytics, helping biotech, pharmaceutical, and healthcare companies leverage data for drug development, clinical trials, and regulatory compliance. Our advanced SAS-based statistical analysis and cloud-based solutions provide powerful tools for drug safety assessment, predictive modelling, and real-world evidence (RWE) generation. Our Mission : We are dedicated to advancing biostatistics and drug analytics through scalable, cloud-based SaaS platforms.Develop innovative solutions for clinical trial data management and analysis.Enable statistical modelling and predictive analytics for drug discovery and safety monitoring.Provide real-world evidence (RWE) platforms to support regulatory decisions.Enhance pharmacovigilance and adverse event reporting with AI-driven insights.Ensure compliance with regulatory standards (FDA, EMA, ICH-GCP) through secure and validated analytics. Our Vision : Accelerate drug development with AI-enhanced statistical modelling.Optimise clinical trial workflows with real-time data processing.Improve patient safety through automated pharmacovigilance.Ensure compliance and transparency in regulatory submissions.Leverage machine learning and big data for precision medicine and biomarker discovery.

Founded in 2018 by a group of experienced professionals, Thrius Pharma Expertize is a reliable partner providing complete, start-to-finish solutions. Our main goal is to offer dependable support to businesses in the pharmaceutical, food, nutraceutical, chemical, healthcare, and related industries. Drawing on the in-depth knowledge of our founders, we're dedicated to helping our clients work better, become more efficient, and achieve lasting growth through customized, joined-up solutions. We know that these industries have complex needs and rules. At Thrius, we're proud of our ability to manage projects smoothly, from the initial idea and planning all the way through to putting them into action and providing ongoing help. Our focus on quality, dependability, and making our clients happy makes us a valuable resource for companies looking for expert advice and reliable execution for their important projects.

Manufacturer of complex molecular intermediates intended for pharmaceutical synthesis and drug development purposes. The company offers asymmetric catalysis, chiral induction, enzyme catalysis, and salting-out crystallization technologies to support the production of high-barrier, high-difficulty active pharmaceutical ingredients and intermediates, serving global pharmaceutical companies to accelerate new drug development, enhance synthesis efficiency, and ensure scalable, quality-controlled manufacturing across clinical and commercial stages.

Operator of the biopharmaceutical company based in Iselin, New Jersey. The company also operates in the field of improving medical treatments and addressing side effects associated with medications.

Join Us for PharmaXNext 2026: The Future of Pharma is Here! 🌟 We are thrilled to announce the International Conference on AI, Biotechnology, and Digital Transformation in Pharma, taking place on February 19-20, 2026, in the vibrant city of Madrid, Spain. 🔬 Conference Purpose: PharmaXNext aims to bring together the brightest minds in AI, biotechnology, and digital transformation to explore the cutting-edge innovations shaping the future of the pharmaceutical industry. This conference is designed to foster collaboration, spark new ideas, and drive advancements in healthcare and pharmaceutical sciences. 🎯 Themes and Highlights: Healthcare 4.0: AI Revolution in Medicine Advanced Drug Delivery Systems AI & ML in Pharmaceutical Industry Clinical Trials & Case Studies Telemedicine Supply Chain AI Accelerates: Drug Discovery & Development Pharmaceutical Technology Personalized Medicine Pharmaceutical Research & Development Pharmacovigilance & Drug Safety Pharma Market & Industry Report Next-Gen Bio Manufacturing 5.0 Data-Driven Health: Big Data Analytics Future of Pharma & Ingredients Pharmaceutical Packaging AI for Pharma: Innovations & Solutions Biopharma: Opportunities & Challenges Generative AI Comparative Study: Science & Research Digital Health Pharmaceutical Modelling Precision Pharma: AI's Next-Gen Role in Medicine

Intelligencia AI uses artificial intelligence to de-risk drug development. Our platform focuses on estimating the risk of clinical trials, and interpreting the multitude of factors that contribute to that risk. We bridge the gap between innovation and risk reduction, with the ultimate goal of bringing novel therapies to patients faster. Our interdisciplinary team of software engineers, AI practitioners, scientists, and drug developers combines and interprets disparate data across the life sciences industry. Our platform offers a suite of functionalities that provide unprecedented data clarity and Machine-Learning predictions to enable critical decision-making. We currently work with several of the largest global pharmaceutical companies as well as mid-size and smaller biotechnology companies. Diseases will impact nearly every individual. At Intelligencia AI, we work to make a difference.

CDMO world is the leading global hub for pharmaceutical CDMO professionals. Explore trends in drug development, manufacturing, CMC, outsourcing, and supply chain. Join industry experts shaping the future of contract pharma.

Sanofi Ventures is the corporate venture capital arm of Sanofi. We have the ability to seed and to lead financings in early-stage companies with innovative ideas and transformative new products and technologies that are of strategic interest to Sanofi. Among these areas are rare diseases, oncology, immunology and inflammation, vaccines, potential cures in other core areas of Sanofi’s business footprint, and digital health and data science solutions.

Provider of intelligent laboratory automation services intended for pharmaceutical research purposes. The company offers artificial intelligence for drug discovery workflows, embodied intelligence for robotic handling, and advanced data processing capabilities, enabling pharmaceutical laboratories to reduce reliance on manual operations, improve reproducibility of experiments, and accelerate development timelines.

Continua is focused on transforming the enterprise through innovative thinking, advanced technologies, and industry expertise. Its team of consultants empowers clients with solutions that span modern data strategies, manufacturing operations solutions, tech transfer, process analytical technology (PAT), and continuous manufacturing. The business primarily serves pharmaceutical, biopharmaceutical, CDMO, CMO, and specialty chemical organizations that are facing growing pressures to leverage OT data, connect disparate systems, and realize higher production to better compete in the marketplace and prepare for the future.

PharmaTutor21 has been created with the aim to create an interactive platform which could provide unprecedented support to novice pharmacy students and researchers in their day to day doubts and also to increase the awareness among the student about this field and introduce the various upcoming areas of research and job opportunities.

Pharm Connection is a specialized consultancy firm bridging the gap between pharmaceutical companies and healthcare professionals in Thailand. We provide targeted educational services, in-depth market research, and strategic consulting to effectively communicate and utilize the latest pharmaceutical innovations. Our mission is to enhance healthcare outcomes by sharing cutting-edge pharmaceutical knowledge with the right people. We work with leading pharmaceutical companies and healthcare institutions to develop tailored solutions that drive growth and success. Our experienced team brings expertise from across the pharmaceutical and healthcare sectors. We offer comprehensive services including onsite and online training, product launch support, market research, medical writing, strategic consulting, and e-learning solutions. As a trusted partner, we help clients navigate the complex challenges of the pharmaceutical industry. Contact us to learn how we can help you bridge the gap between pharma and healthcare. Our comprehensive range of services includes: - Onsite and online training programs - Product launch strategy and support - In-depth market research and analysis - Scientific and medical writing services - Strategic consulting and advisory services - Customized e-learning solutions With a focus on building long-term, collaborative relationships, we strive to be a trusted partner to our clients, helping them navigate the complex challenges and opportunities of the pharmaceutical industry. Our track record of success and satisfied clients speaks to the value we bring to every engagement.

We are an entrepreneurial pharmaceutical company working to drive change in rare diseases.  We're on a mission to help diagnosis and get new drug treatments into the hands of rare disease patients. Quickly. Safely. Cost-effectively. Firstly we help hospital systems better identify and diagnose rare disease patients by analyzing existing electronic health records. Our advanced analytical service helps healthcare systems identify undiagnosed patients, drawing out rare disease cases like a magnet finding needles in a haystack. Our analytics service is powered by a validated software model and provides additional clinical and commercial insights into rare disease populations and resource prioritization. Whether you are searching for a single rare disease or multiple among your patient population, we can help. However, when a rare disease patient is diagnosed, only 5% of rare diseases have an approved therapy and we are trying to change this. We breathe new life into assets that have not been fully unlocked. We acquire drug candidates that demonstrate, from existing safety and efficacy data, a promising path to approval in rare disease indications where there's no current treatment. We are building a broad, late-stage portfolio that is designed to deliver regulatory approvals in a shorter time and with higher probability than more traditional early-stage biotechnology business models.

CiNTL Pharma B.V. is a contract research organization (CRO) that provides clinical research development and data driven solution services to the pharmaceutical, biotechnology and life sciences industries. At CiNTL Pharma our vision is to become a leading CRO led by project management experts leveraging artificial intelligence (AI) to deliver innovative solutions, enhance decision-making, and accelerate the drug development process. Our mission is to provide exceptional CRO services powered by advanced AI technologies that optimize clinical research processes, drive efficiency, and ensure the delivery of high-quality, reliable data for pharmaceutical and biotechnology companies worldwide. Driven By Data Led By Compassion

At Intelligence Connected, we provide transformative solutions tailored to the unique challenges of modern industries. From AI-driven innovation to intelligent platform design and digital ecosystems, our expertise accelerates progress and delivers measurable outcomes. Explore how we can partner with you to redefine what’s possible in your industry.

Operator of a disruptive technology intended for targeting the decisions that are made in the drug development process. The company offers a tool that helps accelerate the process of drug development, reduces the cost and time taken to get the medicines to market, allows medicines to be tested using software, removes the need for unnecessary environmental impacts, enabling businesses to predict toxicological effects and the viability of new drugs.

Molecular Health is a leading provider of data-driven software technology and solutions. For more than 15 years, Molecular Health has been dedicated to building software solutions that leverage a unique symbiosis of human expertise, state-of-the-art data curation, and deep analytics. Molecular Health's proprietary Dataome technology integrates and contextualizes biomedical, molecular, and drug-related data to provide a profound understanding of the etiology of health and disease conditions. Based on the Dataome technology, Molecular Health offers leading-edge software for analyzing genetic and molecular data as well as Pharma AI solutions to improve early trial design, target identification, as well as indication and biomarker discovery. For more information about Molecular Health, please visit www.molecularhealth.com.

BioIntel AI tracks the impact of artificial intelligence across the life sciences industry — from drug discovery and clinical trials to medical affairs and supply chain. We publish case studies, tool breakdowns, and expert insights to help pharma and biotech professionals stay ahead of the AI curve.

PharmaIndiaMagazine is India’s leading online media platform dedicated to the pharmaceutical ingredients and manufacturing industry. Its print counterpart, Pharmaceutical Ingredients Review, is published by I-Tech Media Pvt. Ltd., one of India’s most dynamic B2B media houses. Serving as an authoritative voice of the industry, Pharma India Magazine connects professionals, innovators, and policymakers who are shaping the future of India’s pharmaceutical ecosystem. With a strong focus on innovation, compliance, and technology integration, the platform provides readers with deep insights into the trends transforming modern pharmaceutical production—from raw materials and process technologies to automation, packaging, and digital transformation. We cover the entire pharmaceutical value chain, including ingredients and raw materials (APIs, excipients, intermediates, additives), manufacturing technologies (equipment, validation, automation, quality control), packaging and labelling (serialization, sustainability), regulatory compliance (GMP, USFDA, EMA, WHO), R&D and innovation (drug delivery, nanotech, AI-based solutions), supply chain and logistics (cold chain, warehousing, digital inventory), and sustainability (green manufacturing and EHS). Each issue delivers exclusive interviews, technology insights, market analyses, and expert perspectives—empowering industry professionals to make informed, future-ready decisions.

At Callan Pharma, we specialize in ophthalmic and parenteral drug formulations, solving complex challenges in small molecules, polymer excipients, and nanoparticle systems. With expertise in CMC, IP strategy, and regulatory approvals, we help biotech and pharma companies accelerate drug development. What we do: • Specialized formulations – Ophthalmic, injectable, and subcutaneous drug delivery solutions • Polymer chemistry & Nanotechnology – Enhancing solubility and bioavailability • IP & regulatory strategy – Patent protection and global regulatory navigation • Agile development – Fast, science-driven solutions to keep innovation on track Why partner with Callan Pharma? • A science-first approach blending formulation, IP, and regulatory strategy • A trusted partner for biotech and pharma innovators facing complex formulation challenges

Noven Pharmaceuticals, Inc. is a dynamic specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products. We are committed to developing and offering pharmaceutical products that meaningfully benefit patients, with a commitment to advancing patient care through transdermal drug delivery. Over 300 Noven colleagues are working to advance our business and benefit patients at locations in Miami, FL, Jersey City, NJ. We are a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., the world’s largest manufacturer of transdermal patches, and we serve as Hisamitsu's growth platform for U.S. prescription pharmaceuticals. Noven maintains state-of-the art, FDA-approved transdermal manufacturing facilities in Miami with capacity to produce several hundred million patches per year. These facilities are also approved by the U.S. DEA (Drug Enforcement Agency) for the production of controlled substances.

iDD is a Digital Drug Development organization formed by a group of experienced Clinical Research professionals and Techies in order to implement technology-based solutions for drug development process. iDD was set up with an innovative approach to develop first-of-its-kind technology solutions that are integrated, dynamic and flexible to control the clinical study conduct remotely. In addition to its data capturing technology iDD products have the control systems as its crux to give the ultimate benefit of significantly reducing cost and time of drug development by using iDD’s i-Trial Concept (a virtual trial management process). This will also enable real time access to the data and identify potential risk and signals proactively. The iDD's products are meant to digitize all possible aspects of Clinical Trial conduct at site level by implementing key components of e-Source, e-ICF, e-TMF, Digital Protocol, Digital/Virtual Clinical Trial to get access to trial data on actual real time by integrating all data source to a centralized data capturing system and transfer the same to analytical and monitoring teams of all stake holders for review and identify the issues to mitigate the risks proactively. One more salient feature of iDD's products is the trigger system that addresses risks quicker than ever by predictive analytics. Apart from the technology solutions, iDD also offers end to end cost-effective clinical trial management services with highest standard of quality to Pharmaceutical, Biotechnology, Neutraceuticals, Cosmetic, Medical device companies. As a company we consistently strive to be the best drug development partner for you with adequate flexibility to satisfy your unique needs as per the requirement. Go ahead and explore our site to learn how we can make your trial management woes a thing of the past! "

Our team provides AI implementation strategies for life science and digital healthcare businesses. 70% of organization's AI projects are still stuck in the pilot phase. We help these businesses by laying out a detailed roadmap for creating an AI technology ecosystem. 4. The key benefits may include increased productivity, innovation, sales, job satisfaction, and decreased costs.

Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe. Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections. Debiopharm completed the development and has licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl® -Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat® If your university or biotech start-up has interesting molecules in early-stage research and you’re seeking a competent and committed partner to develop them further, please contact us!